InvestSMART

Neurotech International Limited (ASX:NTI)

ALERT: Price-sensitive ASX Announcement for NTI
Current share price for NTI : $0.016 0.002 (14.29%)+
Announcement
Release
2 Jul 2026 9:35AM
Price at Release
$0.014
Full Release
download
Summary
Neurotech International Limited announced that it has received Notices of Allowance from the United States Patent and Trademark Office for two U.S. patent applications related to NTI164, a proprietary formulation for treating neurological disorders, including autism spectrum disorder (ASD). These patents, once granted, will offer intellectual property protection through 2042, aligning with Neurotech's strategy to expand its global IP portfolio. NTI164 is currently in Phase 3 clinical development for ASD treatment. The company is focused on achieving key milestones for NTI164 as it enters the new financial year.
Key Points
  • Neurotech received Notices of Allowance for two U.S. patent applications.
  • Patents will protect NTI164 until 2042.
  • NTI164 is in Phase 3 development for treating ASD.
  • Neurotech aims to expand their global IP portfolio.
  • Patents cover methods for reducing neuroinflammation and treating ASD.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.